x min read

Vivos Inc (OTCMKTS:RDGL) Surging After Sarcoma Treatment Breakthrough And Toxic Debt Elimination

Vivos Inc (OTCMKTS:RDGL) Surging After Sarcoma Treatment Breakthrough And Toxic Debt Elimination
Written by
Jim Bloom
Published on
September 28, 2018
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook
InsidrFinancial

Vivos Inc. (OTCMKTS:RDGL) has received a lifeline, after coming under immense selling pressure. A plunge below the $0.01 mark had raised serious concerns about the company’s ability to continue operating as a going concern. The stock has since rallied by more than 100%. The rally continues to arouse suggestion of a possible change in the direction of trade.

Vivos Inc. Price Analysis

The meteoric rise from all-time lows follows the announcement of a breakthrough on the company’s candidate treatment for canine Sarcoma. In addition, the company is fresh from signing standstill agreements as part of the latest push to eliminate toxic debt. RDGL Daily ChartThe stock is currently trading in a steep uptrend as the emerging uptrend continues to gain pace. With the stock trading at the $0.02 level, it faces immediate support at the $0.01 mark on any pullback. A breach of the critical support level could open the door for the stock to continue trading lower as has been the case, the better part of the year. On the upside, the stock needs to breach the $0.03 mark, to confirm the bottoming out thesis.

What Does Vivo Inc.? Do?

Vivos Inc. casts itself as a pharmaceutical company focused on research and development of invasive treatments for combating cancer in humans and animals. The company has developed IsoPet, an injectable device for treating tumors in animals. The human version of the device is known as Radiogel.

Recent Development

After a ferocious plunge to all-time lows, Vivos Inc. has bottomed out on a string of positive developments. Fuelling the current upward momentum is the announcement of positive development on the use of IsoPet to treat hind-leg soft tissue sarcoma at the University Of Missouri Veterinary Health Center in Columbia.According to Veterinary oncologist Charles Maitz, treatment of the Sarcoma with IsoPet resulted in a complete response. Tumor destruction and disappearance, further affirm the credibility of the device in tumor treatment.Post-treatment imaging using IsoPet successfully addressed questions previously raised by the Food and Drugs administration review panel.

“The successful treatment of the cat and dog subjects thus far increases the likelihood of IsoPet® becoming a practical solution in the treatment of animal cancer. Additionally, the data obtained at the University of Missouri will support the pre-clinical investigations required by the FDA to provide evidence that Radiogel™ can be safe and effective for treating various human cancer,” said CEO Mike Korenko.

Following the successful trials, the University of Missouri has started advertising the availability of IsoPet treatment, for dogs and other patients.

Debt Elimination Push

In addition to the successful clinical trials, Vivos Inc. sentiments in the market have received a boost on the company announcing plans to get rid of toxic debt. Debt holders of the company’s secured convertible debt have agreed to a ten trading day market standstill.The standstill period is to run from September 26, 2018, to October 10, 2018. Under the terms of the agreement and subject to completion of capital raise of at least $500,000 the remaining balance of the secure debentures is to convert into common stock. Consequently, the debt holders will own approximately 4.99% of the company’s common share at a fixed conversion price of $0.004.The debt restructuring push is part of the company’s latest push to have new capital come in, in the form of common stock and warrants.

“Upon the successful completion of these transactions, we plan to have a company free of toxic convertible debt moving forward. We are confident that we will be successful, but there is no guarantee that we will complete the transactions described above,” said Mr. Korenko.

The Chief Executive officer has also confirmed that they remain open to considering additional financing in the form of debt that converts into a larger equity financing.

Bottom Line

Vivos Inc. is not yet out the red, despite the recent blockbuster run from all-time lows. The fact that the stock is still engulfed in a steep downtrend should worry prospective investors. However, the company has shown it has on its sleeve a product that could take it to new heights in the treatment of tumors in animals and humans.Positive trials of IsoPet at the University of Missouri is a testament that the company has a valuable product from which it could generate long-term value going forward. After the recent price surge, it may be wise to wait for further confirmation before considering the stock a long term play.We will be updating our subscribers as soon as we know more. For the latest updates on RDGL, sign up below!Disclosure: We have no position in RDGL and have not been compensated for this article.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.